Table 4.

Proportional meta-analysis of the frequency of adverse events.

	Frequency of AE	95% CI	Chi-square	p	PI	Included studies (n)	Included patients (n)
Pasireotide
SAE	0.17	0.04, 0.49	0.6	0.219	–	8	522
Diabetes	0.21	0.15, 0.28	2.1	0.076	0.11, 0.36	8	522
Randomized only	0.25	0.21, 0.30	0	–	–	2	312
Hyperglycemia	0.29	0.15, 0.49	18.4	0	0.06, 0.72	8	522
Randomized only	0.48	0.42, 0.53	0	–	–	2	312
Diarrhea	0.3	0.16, 0.48	17.7	0	0.08, 0.68	5	467
Cholecystitis	0.13	0.02, 0.54	73.2	0	0, 0.92	5	467
Randomized only	0.38	0.33, 0.44	0	–	–	2	312
Nausea	0.21	0.12, 0.33	7.8	0.003	0.06, 0.50	5	467
Randomized only	0.29	0.24, 0.34	0	–	–	2	312
Abdominal pain	0.29	0.14, 0.49	0.8	0.18	–	3	331
Randomized only	0.21	0.16, 0.25	0	–	–	2	312
Headache	0.24	0.19, 0.28	0	–	–	3	331
Randomized only	0.23	0.18, 0.28	0	–	–	2	312
Fatigue	0.2	0.16, 0.25	0	–	–	4	363
Cabergoline
Escape from treatment	0.14	0.09, 0.21	0	–	–	6	143
Vertigo	0.12	0.07, 0.19	0	–	–	6	143
Nausea	0.1	0.06, 0.16	0	–	–	6	143
Fatigue	0.07	0.03, 0.18	0.1	0.373	–	6	143
Ketoconazole
Elevated transaminasesa	0.14	0.11, 0.18	0	–	–	8	366
Diarrhea and/or abdominal pain	0.08	0.04, 0.18	2.6	0.052	–	8	366
Rash	0.03	0.01, 0.09	2.4	0.06	–	8	366
Adrenal insufficiency	0.06	0.04, 0.10	0.2	0.327	–	8	366
Metyrapone
Nausea	0.18	0.07, 0.40	1.9	0.085	–	4	89
Vertigo	0.17	0.10, 0.26	0	–	–	4	89
Hirsutism	0.17	0.10, 0.26	0	–	–	4	89
Fatigue	0.07	0.01, 0.40	0.1	0.351	–	4	89
Hypokalemia	0.09	0.05, 0.17	0	–	–	4	89

AE, adverse events; CI, confidence interval; Chi-square, heterogeneity; PI, predictive interval; SAE, serious adverse events.

^aIncludes an increase in alanine aminotransferase and alkaline phosphatase.